Depigmentation Cases Prompt New Label Warning for ADHD Patch

After dozens of reports of skin depigmentation or hypopigmentation associated with use of the methylphenidate transdermal system marketed as Daytrana, FDA officials are requiring that a new warning be added to the medication's package label.
Source: AAFP News - Category: Primary Care Source Type: news